What is Anti Malarial Drug Market Scope?
Antimalarial Drugs are used to treat and prevent malaria disease. The majority of antimalarial medications are directed at the erythrocytic stage of malaria infection, which is the stage of infection that results in symptoms. For most antimalarial medicines, the level of pre-erythrocytic (hepatic stage) action is unknown. Malaria induced by all malaria species requires treatment of the acute blood stage infection. Furthermore, for infections caused by Plasmodium ovale or Plasmodium vivax, terminal prophylaxis with a hypnozoite-killing medication is essential (which can remain dormant in the liver for months and, occasionally, years after the initial infection).
The Anti Malarial Drug market study is being classified by Type (Chloroquine Phosphate, Artemisinin and Others) and major geographies with country level break-up.
The demand for Nucleic Acid Electrophoresis is increasing with each passing day. Businesses in this area face fierce rivalry on a global basis from market leaders who control a large share of the market. The Leading Players are engaged in organic and non-organic strategic global expansion to maintain their Market Position. Analysts at AMA predicts that Players from United States will contribute to the maximum growth of Global Anti Malarial Drug market throughout the predicted period.
Cadila Healthcare (India), Alvizia Healthcare Pvt. Ltd. (India), Novartis (Switzerland), Pfizer (United States), Roche Holding AG (Switzerland), Sun Pharmaceuticals (India), GlaxoSmithKline (United Kingdom), Glenmark Pharmaceuticals (India), Merck & Co (United States) and Cipla (India) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Wallace Pharmaceuticals (India), Bliss GVS Pharma (India) and Ipca Laboratories Ltd (India).
Analyst at AMA have segmented the market study of Global Anti Malarial Drug market by Type, Application and Region.
On the basis of geography, the market of Anti Malarial Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
On September 29 Novartis released a statement announcing the success of its New non-artemisinin combination in a Phase 2b study with Medicines for Malaria Venture (MMV). The researchers combined ganaplacide, a novel drug with a completely different mode of action, with a new lumefantrine formulation optimized for once-daily dosing. This combination has the potential to not only cure malaria infection, including artemisinin-resistant forms but also to prevent the parasite from spreading. Ganaplacide fulfilled the primary study goal in children under the age of 12 years old in Phase 2b research.
Influencing Market Trend
- Rapid Development of Plant-Based Antimalarial Drugs
- The SRising Incidence of Malaria Cases and Deaths in African, Asia, Eastern Mediterranean and Western Pacificurge in Disease by Malaria across the Globe
- Increased Demand of Antimalarial Drug by Travelers
- Rising Incidence of Malaria Cases and Deaths in African, Asia, Eastern Mediterranean and Western Pacific
- Side-Effects of Antimalarial Drugs Such as Dizziness, Headache, and Sleep Disturbances
- The Emergence of Parasite Bacteria
Key Target AudienceVenture and Capitalist, New Entrants/Investors, Analysts and Strategic Business Partners, Hospitals, Clinics and End-Use Industries
Customization available in this Study:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.
Frequently Asked Questions (FAQ):
1. At what growth rate would the Anti Malarial Drug market expands?
The Global Anti Malarial Drug market is expected to see a growth of % during projected year 2020 to 2026.
2. Who are the prominent players of the Global Anti Malarial Drug market?
The prominent players of Global Anti Malarial Drug market are Cadila Healthcare (India), Alvizia Healthcare Pvt. Ltd. (India), Novartis (Switzerland), Pfizer (United States), Roche Holding AG (Switzerland), Sun Pharmaceuticals (India), GlaxoSmithKline (United Kingdom), Glenmark Pharmaceuticals (India), Merck & Co (United States) and Cipla (India), to name a few.
3. What are the top priorities to focus for Anti Malarial Drug marketís growth?
In this highly competitive & fast evolving Anti Malarial Drug industry, the top strategic priorities would remain consistent like innovation, R&D and M&A.